Prostate News and Research

RSS

Signaling between protein, growth factor is critical for coordinated cell migration

The mysterious process that orchestrates cells to move in unison to form human and animal embryos, heal wounds, and even spread cancer depends on interaction between two well-known genetic signaling pathways, two University of Utah medical school researchers have discovered.

11 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Saw Palmetto for enlarged prostate

Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.

6 Nov 2008

Racial disparities increasing for cancers unrelated to smoking

A new American Cancer Society study finds that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking-related cancers, and that cancer mortality differences related to screening and treatment may still be increasing.

6 Nov 2008

Lung airway cells activate vitamin D and increase immune response

Vitamin D is essential to good health but needs to be activated to function properly in the human body.

5 Nov 2008

Bladder conditions - raising awareness

November is Bladder Health Month, and there's no better time to raise awareness of the bladder conditions that affect millions of patients, who often suffer in silence with common, treatable symptoms.

4 Nov 2008

Selenium and vitamin E supplements do not prevent prostate cancer

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

28 Oct 2008

Vitamin E and selenium do not prevent prostate cancer

A major study on whether vitamin E and selenium prevent prostate cancer has been stopped because the supplements are not effective and also because there is a suspicion of a risk.

28 Oct 2008

Statins show promise for deep vein thrombosis

Statins, the class of drugs commonly used for lowering cholesterol, are now showing promise at preventing deep vein thrombosis (DVT) or blood clots, an affliction that occurs in nearly 2 million Americans each year.

27 Oct 2008

Sensitive ultrasound to spot early-stage cancer

European researchers have developed highly sensitive ultrasound equipment that can detect tiny quantities of reflective microbubbles engineered to stick to specific tumour cells. The technique should pick up tumours early and improve patients' chances of survival.

26 Oct 2008

Scientists grow prostates from mouse stem cells

A team of molecular biologists in the U.S. have grown complete prostates derived from stem cells in the prostates of mice and they say the experiment represents a big step towards regenerating organs from a patients' own cells.

23 Oct 2008

Nymox nears completion of benign prostatic hyperplasia drug trial

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.

23 Oct 2008

Mylan receives tentative FDA approval for generic versions of Benicar and Uroxatral

Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg.

22 Oct 2008

Chance of dying from cancer before the age of 84 is falling

The chance of dying from cancer before the age of 84 is becoming much smaller for most types of cancer and should continue falling over the next 20 years according to a new study from Cancer Research UK.

19 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Weight linked to prostate cancer death

New research, funded in part by the Canadian Cancer Society, shows that men suffering from prostate cancer are up to 2 1/2 times more at risk of dying from the disease if they are overweight or obese. The men who participated in the study had been weighed prior to being diagnosed with prostate cancer.

5 Oct 2008

New advance in robotic prostate surgery

To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.

2 Oct 2008

Raised risk of prostate cancer in Black men

Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.

2 Oct 2008